REG - Shield Therapeutics - Block Listing 6 Monthly Return
RNS Number : 6311NShield Therapeutics PLC30 September 2021Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 30 September 2021
Name of applicant:
SHIELD THERAPEUTICS PLC
Name of scheme:
Shield Therapeutics Retention Share Plan
Period of return:
From:
01 April 2021
To:
30 September 2021
Balance of unallotted securities under scheme(s) from previous return:
39,794
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
NIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
39,794
Name of applicant:
SHIELD THERAPEUTICS PLC
Name of scheme:
Shield Therapeutics plc 2016 Company Share Option Plan
Period of return:
From:
01 April 2021
To:
30 September 2021
Balance of unallotted securities under scheme(s) from previous return:
388,079
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
NIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
-47,059
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
341,020
Name of applicant:
SHIELD THERAPEUTICS PLC
Name of scheme:
The Shield Therapeutics plc 2016 Long Term Incentive Plan
Period of return:
From:
01 April 2021
To:
30 September 2021
Balance of unallotted securities under scheme(s) from previous return:
24,273
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
NIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
24,273
Name of applicant:
SHIELD THERAPEUTICS PLC
Name of scheme:
Shield Therapeutics Retention and Performance Share Plan
Period of return:
From:
01 April 2021
To:
30 September 2021
Balance of unallotted securities under scheme(s) from previous return:
3,178,276
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
NIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
3,178,276
Name of contact:
Lucy Huntington-Bailey
Telephone number of contact:
+44 (0) 191 511 8500
For further information, please contact:
Shield Therapeutics plc
+44 (0) 191 511 8500
Greg Madison (CEO)
Hans-Peter Rudolf (CFO)
Peel Hunt LLP - Nominated Adviser & Joint Broker
+44 (0) 20 7148 8900
James Steel / Christopher Golden
finnCap Ltd - Joint Broker
+44 (0) 20 7220 0500
Geoff Nash / Alice Lane/ George Dollemore
Walbrook PR - Financial PR & IR Adviser
+44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne/ Alice Woodings
or shield@walbrookpr.com
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK, Switzerland and Australia and has exclusive IP rights until the mid-2030s. The Group is currently launching Accrufer® in the US. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDBLREAKNEDAEFEFA
Recent news on Shield Therapeutics
See all newsREG - Shield Therapeutics - Notice of Results
AnnouncementREG - Shield Therapeutics - Unaudited Full Year Trading Update
AnnouncementREG - Shield Therapeutics - Appointment of new Chief Financial Officer
AnnouncementREG - Shield Therapeutics - Q3 2023 U.S. Commercial Highlights
AnnouncementREG - Shield Therapeutics - PDMR Transaction Notification
Announcement